ARS Pharma reports Q1 net loss $10.3M; neffy PDUFA date Oct 2, 2024; cash $223.6M

ARS Pharmaceuticals, Inc.

Cash and securities $223.6M as of March 31, 2024; expected operating runway at least three years.
Net loss $10.3M for Q1 2024 compared to $15.0M in Q1 2023; R&D expenses $5.2M, G&A $8.0M.
FDA PDUFA target date for neffy NDA is October 2, 2024; CRL response submitted April 2.
European CHMP opinion on neffy MAA expected in Q2 2024; Day 180 response submitted April 30.
Exclusive license agreement with CSL Seqirus for Australia and New Zealand; up to $5M in payments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARS Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.